ClinicalTrials.gg
RecruitingNCT03694626Updated Sep 8, 2026

Objectively Diagnose and Monitor Treatment of Light Sensitivity

An interventional study of Pupillography and Ocular Coherence Tomography (OCT) in Photophobia, Traumatic Brain Injury and Migraine, sponsored by Randy Kardon. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Randy Kardon · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.

Read the detailed description

Using objecting measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light this project aims to provide a new framework for diagnosing and monitoring treatment of light sensitivity. The patient's responses will be measured with videography facial muscle electrical responses Electromyogram (EMG) measured from surface skin electrodes and retinal electrical responses (EMG) or electroretinogram (ERG) recorded from a portable hand-held device). Simultaneously, patient's will have their heart rate and skin conductance objectively monitored using wristwatch devices (E4, Empatica). If successful, this will open an immediate new way to objectively assess the mechanisms that lead to light sensitivity, and provide an approach to effectively treat, and manage the symptoms of light sensitivity and headache from different causes, including traumatic brain injury (TBI) and migraine.

02

Conditions studied

  • Photophobia
  • Traumatic Brain Injury
  • Migraine
03

In context

Photophobia

43 studies on the registry are indexed under Photophobia; 13 are open to participants now.

This study's planned enrollment of 120 is above the median of 43 across 36 interventional studies indexed under Photophobia.

Browse Photophobia studies →

Lead sponsor

Randy Kardon is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Healthy Control subjects:

Inclusion Criteria

  • Healthy individuals with normal eye exam in the previous year
  • Age 18-80

Exclusion Criteria

  • History of eye or systemic disorder that affect the retina, optic nerve, visual pathway, or pupil defect: including glaucoma, optic neuropathy, or retinal disease, diabetes and/or hypertension that are not well controlled, history of head trauma, concussion, or TBI, history of cervical or spinal injury/surgery
  • Medications or eyedrops that would confound measuring the pupil light reflex and EMG: including topical autonomic drugs that could influence pupil size, ocular pharmacologic agents, sedative agents (e.g. benzodiazepines or barbiturates), opioid narcotics
  • Must not be light sensitive or get migraine headaches

TBI patients without photosensitivity or headache:

Inclusion Criteria

  • Age 18-80
  • Traumatic Brain Injury (TBI)

Exclusion Criteria

  • History of eye or systemic disorder that affect the retina, optic nerve, visual pathway, or pupil defect: including glaucoma, optic neuropathy, or retinal disease, diabetes and/or hypertension that are not well controlled
  • Medications or eyedrops that would confound measuring the pupil light reflex and EMG: including topical autonomic drugs that could influence pupil size, ocular pharmacologic agents, sedative agents (e.g. benzodiazepines or barbiturates), opioid narcotics - Must not be light sensitive or get migraine headaches (use headache criteria from Ana if we are including headaches)

Patients with photosensitivity from non-TBI causes Inclusion Criteria

  • Age 18-80
  • Photosensitivity: determined by patient reporting symptoms and there may or may not be an identified cause associated with their light sensitivity (i.e. history of uveitis, childhood exotropia, meningitis, radiation, tumor)

Exclusion Criteria

  • History of eye or systemic disorder that affect the retina, optic nerve, visual pathway, or pupil defect: including glaucoma, optic neuropathy, or retinal disease, diabetes and/or hypertension that are not well controlled, history of head trauma, concussion, or TBI, history of cervical or spinal injury/surgery
  • Medications or eyedrops that would confound measuring the pupil light reflex and EMG: including topical autonomic drugs that could influence pupil size, ocular pharmacologic agents, sedative agents (e.g. benzodiazepines or barbiturates), opioid narcotics

TBI patients with photosensitivity Inclusion Criteria

  • Age 18-80
  • Photosensitivity: determined by patient reporting symptoms and cause associated with their light sensitivity is post TBI
  • TBI

Exclusion Criteria

- History of eye or systemic disorder that affect the retina, optic nerve, visual pathway, or pupil defect: including glaucoma, optic neuropathy, or retinal disease, diabetes and/or hypertension that are not well controlled

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Healthy Control subjects

    Device: Pupillography · Device: Ocular Coherence Tomography (OCT) · Device: Wrist-watch sensor device · Device: Videography · Device: Electrophysiology

  • Active comparator
    TBI Patients without photosensitivity

    Device: Pupillography · Device: Ocular Coherence Tomography (OCT) · Device: Wrist-watch sensor device · Device: Videography · Device: Electrophysiology

  • Active comparator
    Migraine patients without photosensitivity

    Device: Pupillography · Device: Ocular Coherence Tomography (OCT) · Device: Wrist-watch sensor device · Device: Videography · Device: Electrophysiology

  • Active comparator
    Migraine patients with photosensitivity

    Device: Pupillography · Device: Ocular Coherence Tomography (OCT) · Device: Wrist-watch sensor device · Device: Videography · Device: Electrophysiology

  • Active comparator
    TBI patients with photosensitivity

    Device: Pupillography · Device: Ocular Coherence Tomography (OCT) · Device: Wrist-watch sensor device · Device: Videography · Device: Electrophysiology

Interventions

  • DevicePupillography

    A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.

    Also known as: Reteval, LKC

  • DeviceOcular Coherence Tomography (OCT)

    The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.

  • DeviceWrist-watch sensor device

    A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).

    Also known as: (E4, Empatica)

  • DeviceVideography

    The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next. After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities. At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity.

  • DeviceElectrophysiology

    Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.

06

What researchers measure

Primary outcomes

  1. Correlation of facial responses to light sensitivity

    Hand held pupillography/videography, electroretinogram, and electrophysiology measurements are correlated to develop of an objective biological marker of light sensitivity.

    Time frame: 1 Day

  2. Difference in objective biological markers of light sensitivity between light sensitive and normal subjects

    The correlation of facial responses to light sensitivity is compared between groups to test whether the measure can accurately distinguish light sensitivity.

    Time frame: 1 Day

Secondary outcomes

  1. Correlation of objective biological marker of light sensitivity to optic nerve structures

    Bio marker score will be correlated to optic nerve structure measurements made using Optical Coherence Tomography (OCT) to evaluate structural loss of the optic nerve.

    Time frame: 1 Day

  2. Correlation of objective biological marker of light sensitivity to macula (structure found in the back of the eye).

    Bio marker score will be correlated to macula structure measurements made using Optical Coherence Tomography (OCT) to examine to evaluate structural loss of the macula (structure found in the back of the eye).

    Time frame: 1 Day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We will determine a plan to share IPD closer to time of completion of the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2019 (actual). Primary completion is estimated for Jan 2028, 101 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2018
First posted
Oct 3, 2018
StartActual
Jul 11, 2019
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03694626
Lead sponsor
Randy Kardon
Responsible party
Randy Kardon (Principal Investigator, University of Iowa) — Sponsor-investigator
First posted
Oct 3, 2018
Start date
Jul 11, 2019
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Julie Nellis, BSN
Contact
julie-nellis@uiowa.edu
319-356-2780
Jan Full, BSN
Contact
jan-full@uiowa.edu
3193562780

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion